

JUL 30 2001

SHEET 2 OF 2

FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. RIORD.006A	APPLICATION NO. 09/781,023
	APPLICANT Riordan, N.	
	FILING DATE February 9, 2001	GROUP Unknown

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
NAD	Donald L. Morton et al., <i>Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine</i> , Ann. Surg., October 1992, pp. 463-482.
	N.S. Rote et al., <i>Determination of Incidence and Partial Characterization of Tumor-Associated Antigens Found in the Urine of Patients Bearing Solid Tumors</i> , Int. J. Cancer, Vol. 26, 1980, pp. 203-210.
	Sanford J. Finck et al., <i>Excretion of Tumor-Associated Antigen(s) in the Urine of Patients With Colon Carcinoma</i> , Journal of Surgical Oncology, Vol. 21, 1982, pp. 81-86.
	David M. Euhus et al., <i>Detection of a Tumor-Associated Glycoprotein Antigen in Serum and Urine of Melanoma Patients by Murine Monoclonal Antibody (AD1-40F4) in Enzyme Immunoassay</i> , Journal of Clinical Laboratory Analysis, Vol. 3, 1989, pp. 184-190.
	Ralph W. DeVere et al., <i>Urinary Prostate Specific Antigen Levels: Role in Monitoring the Response of Prostate Cancer to Therapy</i> , The Journal of Urology, Vol. 147, March 1992, pp. 947-951.
	P. Cariuk et al., <i>Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients</i> , British Journal of Cancer, Vol. 76, No. 5, 1997, pp. 606-613.
	Franz Halberg et al., <i>Cancer Marker Assessment: Case Report on Salivary and Urinary CEA, in vivo</i> , Vol. 9, 1995, pp. 311-314.

H:\DOCS\JAH\JAH-4655.DOC:bb
071301

EXAMINER <i>N. Adams</i>	DATE CONSIDERED <i>4-3-02</i>
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
RIORD.006AAPPLICATION NO.
09/781,023

RECEIVED

AUG 03 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Riordan, N.FILING DATE
February 9, 2001GROUP
Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
VAD	Rajender K. Chawla et al., <i>Isolation and Characterization of a Glycoprotein (JBB5) in the Urine of a Patient with Carcinoma of the Colon</i> , <u>CANCER RESEARCH</u> , Vol. 37, March 1977, pp. 873-878.
	Peter A. Cohen et al., <i>CD4⁺ T-Cells from Mice Immunized to Syngeneic Sarcomas Recognize Distinct, Non-Shared Tumor Antigens</i> , <u>CANCER RESEARCH</u> , Vol. 54, February 15, 1994, pp. 1055-1058.
	Frank J. Hsu et al., <i>Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells</i> , <u>NATURE MEDICINE</u> , Vol. 2, No. 1, January 1996, pp. 52-58.
	G. Murphy et al., <i>Phase I Clinical Trial: T-Cell Therapy for Prostate Cancer Using Autologous Dendritic Cells Pulsed With HLA-A02011-Specific Peptides from Prostate-Specific Membrane Antigen</i> , <u>The Prostate</u> , Vol. 29, 1996, pp. 371-380.
	Frank O. Nestle et al., <i>Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells</i> , <u>NATURE MEDICINE</u> , Vol. 4, No. 3, March 1998, pp. 328-332.

EXAMINER

N. J. Riordan

DATE CONSIDERED

4-3-02

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.